Journal
DIABETES
Volume 68, Issue 5, Pages 1002-1013Publisher
AMER DIABETES ASSOC
DOI: 10.2337/db18-0487
Keywords
-
Categories
Funding
- Diabetes UK
- Fulbright-Diabetes UK
- National Institutes of Health [DK-092882, DK-100500, P30-DK-45735]
- European Foundation for the Study of Diabetes grant [NN 2014_6]
- Medical Research Council [G0901155]
- MRC [G0901155] Funding Source: UKRI
Ask authors/readers for more resources
Insulin is a major autoantigen in type 1 diabetes, targeted by both CD8 and CD4 T cells. We studied an insulin-reactive T-cell receptor (TCR) alpha-chain transgenic NOD mouse on a TCRC alpha and proinsulin 2 (PI2)-deficient background, designated as A22C alpha(-/-)PI2(-/-) NOD mice. These mice develop a low incidence of autoimmune diabetes. To test the role of gut microbiota on diabetes development in this model system, we treated the A22C alpha(-/-)PI2(-/-) NOD mice with enrofloxacin, a broad-spectrum antibiotic. The treatment led to male mice developing accelerated diabetes. We found that enrofloxacin increased the frequency of the insulin-reactive CD8+ T cells and activated the cells in the Peyer's patches and pancreatic lymph nodes, together with induction of immunological effects on the antigen-presenting cell populations. The composition of gut microbiota differed between the enrofloxacin-treated and untreated mice and also between the enrofloxacin-treated mice that developed diabetes compared with those that remained normoglycemic. Our results provide evidence that the composition of the gut microbiota is important for determining the expansion and activation of insulin-reactive CD8+ T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available